Cargando…

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma

BACKGROUND: The purpose of the current study was to evaluate the efficacy and safety of a dose increased weekly Bortezomib (Bor) based combination therapy in multiple myeloma (MM) patients. RESULTS: The overall response rate (ORR) in the modified Bor group was 76.6%, composed of 40% complete respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Daolin, Tong, Yin, Bai, Haitao, Cai, Qi, Gao, Yanrong, Wang, Chun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342543/ https://www.ncbi.nlm.nih.gov/pubmed/27659525 http://dx.doi.org/10.18632/oncotarget.12162

Ejemplares similares

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
por: Dolph, Michael, et al.
Publicado: (2021)

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
por: Banerjee, Rahul, et al.
Publicado: (2023)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma
por: Mangiacavalli, Silvia, et al.
Publicado: (2013)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
por: Zaal, Esther A., et al.
Publicado: (2017)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2016)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib
por: Sanchez, W Y, et al.
Publicado: (2013)

Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
por: Song, In-Sung, et al.
Publicado: (2013)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
por: Zhang, Shijia, et al.
Publicado: (2020)

A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
por: Alsina, Melissa, et al.
Publicado: (2020)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
por: Shah, Jatin J, et al.
Publicado: (2009)

Cytotoxic and Apoptotic Effects of Pinostilbene and Bortezomib Combination Treatment on Human Multiple Myeloma Cells
por: Staskiewicz, Anna, et al.
Publicado: (2023)

Solamargine induces autophagy‐mediated apoptosis and enhances bortezomib activity in multiple myeloma
por: Han, Qiaoyan, et al.
Publicado: (2022)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib
por: Zhao, Yinghao, et al.
Publicado: (2015)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
por: Chen, Wendong, et al.
Publicado: (2016)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
por: Starheim, K K, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_26t4lt7vv1e6n4bmknb6reu47k